Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

BACKGROUND: The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy. Recent clinical trials have established the clinical utility of nivolumab in the third-line treatment of such patients. Immune-related adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Arigami, Takaaki, Matsushita, Daisuke, Okubo, Keishi, Tanaka, Takako, Sasaki, Ken, Noda, Masahiro, Kita, Yoshiaki, Mori, Shinichiro, Tsuruda, Yusuke, Kurahara, Hiroshi, Ohtsuka, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572942/
https://www.ncbi.nlm.nih.gov/pubmed/33074364
http://dx.doi.org/10.1186/s40792-020-01050-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572942/
https://www.ncbi.nlm.nih.gov/pubmed/33074364
http://dx.doi.org/10.1186/s40792-020-01050-1

Ejemplares similares